Skin Cancer

The resubmission of the biologics license application for cosibelimab for locally advanced or metastatic cutaneous squamous cell carcinoma follows a complete response letter from the FDA in December 2023.

These data from the COMBI-AD trial represent the longest follow-up to date of adjuvant treatment for stage III melanoma.

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

An oncology nurse and pharmacist discuss the multidisciplinary approach to administering TIL therapy in patients with advanced melanoma.

The first real-time, non-invasive skin cancer evaluation system has received clearance from the FDA.

Lifileucel is the first TIL therapy approved by the FDA for a solid tumor, specifically previously treated unresectable or metastatic melanoma.

Oncology nurses may play a role in the utilization of artificial intelligence in the clinical setting.

Jeanelle S. King, PA-C, provides an in-depth look at nivolumab-relatlimab in a downloadable reference sheet.

The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma.

At 85.3 months follow-up, the median overall survival with pembrolizumab was 32.7 months vs 15.9 months with ipilimumab.

ASCO has updated its recommendations for systemic therapies in melanoma.

The FDA has approved a liver-directed therapy to treat metastatic uveal melanoma with hepatic metastases.

Patients about to undergo Mohs microscopic surgery reported that they were more likely to request over-the-counter medications if they perceived their risk of opioid addiction to be high.

The FDA has launched a priority review of lifileucel based on data from the phase 2 C-144-01 trial.

What are the implications of new approvals for oncology nurses specializing in melanoma?

Adjuvant mRNA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma.

Patients with heavily pretreated advanced melanoma achieved responses with nivolumab and relatlimab.

Cemiplimab has received full approval for patients with metastatic basal cell carcinoma. The most common adverse events include fatigue, musculoskeletal pain, rash, diarrhea, and anemia.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

Retifanlimab has received accelerated approved for patients with metastatic or recurrent, locally advanced merkel cell carcinoma.

Caressa Valdueza, MSN, AGNP-BC, AOCNP, discusses toxicity management with unfolding treatment options in melanoma.

A combination of vusolimogene oderparepvec and nivolumab elicited early clinical activity in patients with cutaneous melanoma whose disease did not response to anti-PD-1 therapy.

APRNs developed a discharge program which reduced readmission rates for patients receiving immunotherapy for advanced melanoma.

Atezolizumab has been granted FDA approval for patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma.

Adjuvant pembrolizumab demonstrated significantly better quality of life outcomes for patients with resected melanoma vs standard care.

All 24 patients with Merkel cell carcinoma who received nivolumab plus ipilimumab responded to treatment, and 41% achieved complete responses.

Sotigalimab, a humanized IgG1 monoclonal antibody against human CD40, may hold value in the frontline treatment of patients with metastatic melanoma.

A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab.

During the 40th Annual Chemotherapy Foundation Symposium, Jeffrey S. Weber, MD, PhD, discussesed best sequencing practices in metastatic melanoma.

Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.